Biosimilars
-
Caught my eye — 10/6/23
Read more: Caught my eye — 10/6/23Patients driving change. I love this story because it involves Carl Schmid, patient groups and copay accumulators. Copay accumulators are when insurance does not allow pharmaceutical manufacturer contributions to count towards patient out-of-pocket spending calculations. Thanks to the HIV+Hepatitis Policy Institute, the Diabetes Leadership Council and the Diabetes Patient Advocacy Coalition and their suit against…
-
Caught my eye — 9/22/23
Read more: Caught my eye — 9/22/23Leave the gun, take the cannoli. House Energy and Commerce hearing on Medicare price negotiation gets feisty. Not often that the mafia comes up on the House floor but an interesting comparison of price negotiation and an offer they can’t refuse. I doubt Congressman Griffith (R-VA) and I agree on much politically but on this,…
Latest news
- Caught my eye — 5/16/25
- Initial Take on MFN Executive Order, Part II
- Caught my eye — 5/09/25
- Don’t Call it a Comeback
- Caught my eye — 5/2/25
Categories
- 340B (38)
- Affordable Care Act (5)
- Alzheimer's (6)
- Biosimilars (22)
- Caught my eye (67)
- Cell and Gene (2)
- Chevron Deference (2)
- CMMI (14)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (36)
- Drug shortages (10)
- DTC (2)
- Employers (8)
- Generics (6)
- Health Equity (3)
- Healthcare Costs (30)
- ICER (10)
- Importation (4)
- Inflation Reduction Act (50)
- Insulin (5)
- IP (3)
- Long term care (1)
- Medicaid (7)
- Medicare Advantage (16)
- Medicare Negotiation (52)
- Medicare Part D (47)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (9)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (32)
- Preventative (2)
- Reference Pricing (8)
- State-based Reform (16)
- Supply Chain (2)
- Uncategorized (7)
- Utilization Management (1)
- Vaccines (4)
- Value (13)